Former CEO of Charles Schwab Investment Management will also serve as audit committee chair RARITAN, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care,

Agencies Provide Stable Outlook Following Company’s Initial Public Offering RARITAN, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), one of the world's largest pure-play in vitro diagnostics companies, today announced that S&P Global (“S&P”)

Increases facility by $150 million and extends it to 2026 RARITAN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), one of the world's largest pure-play in vitro diagnostics companies, today announced that certain of its subsidiaries

RARITAN, N.J. , Feb. 4, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the

RARITAN, N.J. , Jan. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the pricing of its

​​​​​ Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that it was recognized with  MedTech’s 2020 Outstanding Contribution to the Bio/Med Industry Award  for its  diagnostic solutions to the COVID-19 pandemic . Ortho was the first company to receive Emergency

Ortho’s VITROS® SARS-CoV-2 Antigen Test is the first high-volume COVID-19 antigen test to receive Food and Drug Administration (FDA) Emergency Use Authorization (EUA). With utility for mass-scale testing and same-day results for labs, Ortho’s latest COVID-19 solution can run up to 130 tests per

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, today announced the CE Mark availability of the semi-automated ORTHO Optix™ Reader, which allows lower-volume transfusion labs to elevate their

Ortho Clinical Diagnostics (“Ortho”), today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to its proposed initial public offering. The number of shares to be offered and the price range for

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics and the global market leader for transfusion medicine diagnostics, is pleased to announce a full slate of events at the 2020 AABB Annual Meeting, to be held virtually Oct. 3-5. Ortho’s programming will focus on the company’s